(Anti-)TNF alpha matters in rheumatoid arthritis

Title pages

Contents

Chapter 1: General introduction

Chapter 2: The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

Chapter 3: Responsiveness to anti-TNFalpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients

Chapter 4: Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

Chapter 5: Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients

Chapter 6: Sustained changes in lipid profile and macrophage migration inhibitory factor (MIF) levels after anti-TNF therapy in rheumatoid arthritis

Chapter 7: Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy : arrest of bone loss?

Chapter 8: Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients : a cohort study

Chapter 9: Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells : assignment of a type I interferon signature in a subpopulation of patients

Chapter 10: Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype

Chapter 11: Absence of changes in synovial sublining macrophages after ineffective anti-rheumatic treatment : implications for the use as a biomarker

Chapter 13: General discussion and summary

Nederlandse samenvatting

Dankwoord en contemplatie

Curriculum vitae

Bibliography

Abbreviations

Appendix: Color figures